What This Label Expansion Means for Merck
Merck & Co. (NYSE: MRK) announced earlier this month that its blockbuster cancer drug Keytruda was approved by the U.S. Food and Drug Administration (FDA) in combination with Eisai's (OTC: ESALY) Lenvima to treat advanced renal cell carcinoma (RCC, also known as kidney cancer). This comes just weeks after the combo was approved by the FDA to treat patients with certain types of advanced endometrial carcinoma last month.
We'll take a look at what prompted the FDA to approve the Keytruda-Lenvima combination for advanced RCC, as well as how that could translate into growth for Merck in the next few years.
Image Source: Getty Images.
Source Fool.com
